CELCUITY INC
CELCNASDAQTrading Snapshot
- Day Range
- $76.30 – $78.85
- 52-Week Range
- $44.42 – $151.02
- Volume
- $2.15B
- Avg Volume
- $1.61B
- Shares Outstanding
- 48.8M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $293M
- Last Q Revenue
- $69M
- P/E Ratio
- -18.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +22.5%
Why Investors Own CELC
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CELCUITY INC
CELC
StockOtter · stockotter.spaceAbout CELCUITY INC
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, to
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the
Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fun
Celcuity: REVTORPYK Is Now A Commercial Story
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.